Cours suspendu

Communiqués G1 Therapeutics, Inc.

Actions

GTHX

US3621LQ1099

Marché Fermé - Nasdaq 22:00:00 17/09/2024			Varia. 5j.	Varia. 1 janv.
7,150 ^USD	-.--%		-.--%	-

05/09/24	Le projet de fusion entre G1 Therapeutics et Pharmacosmos progresse avec la fin de la période d'attente antitrust	MT
08/08/24	G1 Therapeutics, Inc. réaffirme ses prévisions de résultats pour l'année 2024	CI

Communiqués

18/09/24	Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer	GL
05/09/24	Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period	GL
09/08/24	G1 THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of G1 Therapeutics, Inc. - GTHX	BU
08/08/24	G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights	GL
07/08/24	Pharmacosmos Group to Acquire G1 Therapeutics	GL
02/08/24	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
25/07/24	G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024	GL
02/07/24	G1 THERAPEUTICS ADDED TO THE RUSSELL 2000 AND 3000 INDEXES	AQ
01/07/24	G1 Therapeutics Added to the Russell 2000® and 3000® Indexes	AQ
24/06/24	G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)	GL
06/06/24	G1 THERAPEUTICS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(4)	AQ
05/06/24	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
29/05/24	G1 THERAPEUTICS, INC. - MEANINGFUL IMPROVEMENT IN OVERALL SURVIVAL AND TOLERABILITY OBSERVED IN PATIENTS RECEIVING TRILACICLIB IN COMBINATION WITH A TROP2 ANTIBODY-DRUG CONJUGATE	AQ
28/05/24	Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)	GL
23/05/24	G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting	GL
23/05/24	G1 THERAPEUTICS AND DEIMOS BIOSCIENCES ANNOUNCE GLOBAL LICENSE AGREEMENT FOR LEROCICLIB FOR RADIOPROTECTIVE USES	AQ
23/05/24	G1 THERAPEUTICS TO PARTICIPATE IN TD COWEN'S 5TH ANNUAL ONCOLOGY INNOVATION SUMMIT	AQ
22/05/24	G1 Therapeutics to Participate in TD Cowen’s 5th Annual Oncology Innovation Summit	AQ
22/05/24	G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses	GL
08/05/24	G1 Therapeutics : May 2024 Corporate Presentation	PU
01/05/24	G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
01/05/24	G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights	GL
01/05/24	G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib	GL
17/04/24	G1 Therapeutics to Release First Quarter 2024 Financial Results and Provide Business Update on May 1, 2024	AQ
04/04/24	G1 Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference	AQ